• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Cell-Based Therapies and Treatment of Cardiac Disease

February 13, 2015

85757034Cardiac disease is the number one cause of death in the United States and Europe and costs health systems an excess of $500 billion a year.

Current therapeutics for cardiac disease aim to slow its progression, but new cell-based therapies are now being developed to generate new cardiac tissue. Many cell types such as skeletal myoblasts and bone-marrow or blood-derived cells have been used in trials to treat cardiac disease, but unfractionated bone marrow-derived mononuclear cells have been used in over 2000 patients—more than the other cell types combined. Cells are usually injected directly into the heart through an inflated over-the-wire balloon catheter. Clinical trials demonstrated that cell-based therapies are safe; however, evidence suggests few implanted cells survive and that improvements in patients are independent of new cardiac tissue. Although cell-based therapy is promising for the treatment of cardiac disease, more research is needed to determine the most effective cell type(s), the optimal time of transplantation, and the mechanisms behind the therapy.

Reference

1. Young PP, Schafer R. Cell-based therapies for cardiac disease: a cellular therapist’s perspective. Transfusion 2015; 55:441-451.

 

TRF_CMETransfusion offers CME credit for this study! Log on at www.wileyhealthlearning.com/trf.

 

Filed Under

  • Cell Therapy
  • CME
  • News

Recommended

  • FDA Guidance for COVID-19 Convalescent Plasma to Remain in Effect

  • Updated FDA Guidance for Blood Donor Eligibility for Blood Pressure and Pulse

  • SARS-CoV-2 RNA Frequently Found in Blood Donor Plasma is Not Infectious

Show Comments

Reader Interactions

Comments

  1. Ann Marie Posuniak says

    April 2, 2015 at 6:17 am

    Excellent information

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • RBCs with Reduced Deformability are Removed from Circulation

  • Array-based, comprehensive genotyping for erythroid, platelet, neutrophil and leukocyte antigens

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley